Recent Research Analysts’ Ratings Updates for Merck KGaA (MRK)

Merck KGaA (FRA: MRK) has recently received a number of price target changes and ratings updates:

  • 1/10/2018 – Merck KGaA was given a new €95.00 ($113.10) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock.
  • 1/8/2018 – Merck KGaA was given a new €120.00 ($142.86) price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
  • 1/4/2018 – Merck KGaA was given a new €95.00 ($113.10) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock.
  • 1/2/2018 – Merck KGaA had its “neutral” rating reaffirmed by analysts at Nord/LB.
  • 12/29/2017 – Merck KGaA was given a new €95.00 ($113.10) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock.
  • 12/27/2017 – Merck KGaA had its “neutral” rating reaffirmed by analysts at Nord/LB.
  • 12/13/2017 – Merck KGaA was given a new €115.00 ($136.90) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock.
  • 12/12/2017 – Merck KGaA was given a new €100.00 ($119.05) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock.
  • 12/8/2017 – Merck KGaA was given a new €98.00 ($116.67) price target on by analysts at Nord/LB. They now have a “neutral” rating on the stock.
  • 12/6/2017 – Merck KGaA was given a new €120.00 ($142.86) price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
  • 12/6/2017 – Merck KGaA was given a new €95.00 ($113.10) price target on by analysts at Bank of America Corp. They now have a “neutral” rating on the stock.
  • 12/1/2017 – Merck KGaA was given a new €98.00 ($116.67) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 11/29/2017 – Merck KGaA was given a new €115.00 ($136.90) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock.
  • 11/29/2017 – Merck KGaA was given a new €100.00 ($119.05) price target on by analysts at Goldman Sachs Group Inc. They now have a “neutral” rating on the stock.
  • 11/29/2017 – Merck KGaA was given a new €115.00 ($136.90) price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 11/28/2017 – Merck KGaA had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 11/23/2017 – Merck KGaA was given a new €116.00 ($138.10) price target on by analysts at Berenberg Bank. They now have a “buy” rating on the stock.
  • 11/20/2017 – Merck KGaA was given a new €100.00 ($119.05) price target on by analysts at Goldman Sachs Group Inc. They now have a “neutral” rating on the stock.
  • 11/15/2017 – Merck KGaA was given a new €115.00 ($136.90) price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 11/14/2017 – Merck KGaA had its “neutral” rating reaffirmed by analysts at DZ Bank AG.

Merck KGaA (FRA MRK) opened at €92.50 ($110.12) on Thursday. The company has a market cap of $12,020.00 and a P/E ratio of 21.66. Merck KGaA has a 12 month low of €87.33 ($103.96) and a 12 month high of €115.00 ($136.90).

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit